Strategies to develop antivirals against enterovirus 71

Virology Journal

Volumn 10, Issue , 2013, Pages

  Kuo, Rei Lin ^a,b   Shih, Shin Ru ^a,b,c  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; CAPSID PROTEIN; ENVIROXIME; INTERFERON RECEPTOR; INTERFERON REGULATORY FACTOR 9; LACTOFERRIN; PIRODAVIR; PLECONARIL; RUPINTRIVIR; VIRUS RNA;

ANTIVIRAL RESISTANCE; DRUG EFFICACY; ENTEROVIRUS 71; GENE EXPRESSION; HUMAN; IMMUNITY; IMMUNOMODULATION; IN VITRO STUDY; INNATE IMMUNITY; INTERFERON PRODUCTION; NONHUMAN; POLIOMYELITIS VIRUS; REVIEW; RHINOVIRUS; RNA INTERFERENCE; SURVIVAL RATE; VACCINE PRODUCTION; VIRUS CAPSID; VIRUS ENTRY; VIRUS GENOME; VIRUS MUTATION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, VIRAL; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; HUMANS; IMMUNOMODULATION; RNA INTERFERENCE; VIRAL VACCINES;

ANIMALIA; HUMAN ENTEROVIRUS 71; HUMAN RHINOVIRUS SP.; POLIOVIRUS;

EID: 84872449181     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-28     Document Type: Review

References (78)

1. An apparently new enterovirus isolated from patients with disease of the central nervous system. Schmidt NJ, Lennette EH, Ho HH, J Infect Dis 1974 129 3 304 309 10.1093/infdis/129.3.304 4361245
2. Enterovirus 71 outbreak, Brunei. AbuBakar S, Sam IC, Yusof J, Lim MK, Misbah S, MatRahim N, Hooi PS, Emerg Infect Dis 2009 15 1 79 82 10.3201/eid1501.080264 19116058
3. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang JR, Shih SR, N Engl J Med 1999 341 13 929 935 10.1056/NEJM199909233411301 10498487 (Pubitemid 29441546)
4. Enterovirus 71 from fatal and nonfatal cases of hand, foot and mouth disease epidemics in Malaysia, Japan and Taiwan in 1997-1998. Shimizu H, Utama A, Yoshii K, Yoshida H, Yoneyama T, Sinniah M, Yusof MA, Okuno Y, Okabe N, Shih SR, et al. Jpn J Infect Dis 1999 52 1 12 15 10808253 (Pubitemid 29414613)
5. Enterovirus 71 outbreak in the People's Republic of China in 2008. Yang F, Ren L, Xiong Z, Li J, Xiao Y, Zhao R, He Y, Bu G, Zhou S, Wang J, et al. J Clin Microbiol 2009 47 7 2351 2352 10.1128/JCM.00563-09 19439545
6. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Chang LY, Lin TY, Hsu KH, Huang YC, Lin KL, Hsueh C, Shih SR, Ning HC, Hwang MS, Wang HS, et al. Lancet 1999 354 9191 1682 1686 10.1016/S0140-6736(99)04434-7 10568570 (Pubitemid 29533058)
7. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, Mao N, Xu S, Zhu S, Cui A, et al. Virol J 2010 7 94 10.1186/1743-422X-7-94 20459851
8. Cambodia unravels cause of mystery illness. Seiff A, Lancet 2012 380 9838 206 10.1016/S0140-6736(12)61201-X 22826835
9. Clinical features, diagnosis, and management of enterovirus 71. Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T, Lancet Neurol 2010 9 11 1097 1105 10.1016/S1474-4422(10)70209-X 20965438
10. Retrograde axonal transport: a major transmission route of enterovirus 71 in mice. Chen CS, Yao YC, Lin SC, Lee YP, Wang YF, Wang JR, Liu CC, Lei HY, Yu CK, J Virol 2007 81 17 8996 9003 10.1128/JVI.00236-07 17567704 (Pubitemid 47311443)
11. Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Brown BA, Pallansch MA, Virus Res 1995 39 2-3 195 205 8837884 (Pubitemid 26054785)
12. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H, Nat Med 2009 15 7 794 797 10.1038/nm.1961 19543284
13. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, Koike S, Nat Med 2009 15 7 798 801 10.1038/nm.1992 19543282
14. Enterovirus 71 contains a type I IRES element that functions when eukaryotic initiation factor eIF4G is cleaved. Thompson SR, Sarnow P, Virology 2003 315 1 259 266 10.1016/S0042-6822(03)00544-0 14592777 (Pubitemid 37340067)
15. Picornaviridae: The Virus ans Their Repliation. Racaniello VR, Fields Virology Philadelphia, PA, USA: Lippincott Williams & Wilkins, Knipe DM, Howley PM, 5th 2007 796 839
16. Cellular COPII proteins are involved in production of the vesicles that form the poliovirus replication complex. Rust RC, Landmann L, Gosert R, Tang BL, Hong W, Hauri HP, Egger D, Bienz K, J Virol 2001 75 20 9808 9818 10.1128/JVI.75.20.9808-9818.2001 11559814 (Pubitemid 32900116)
17. Reticulon 3 binds the 2C protein of enterovirus 71 and is required for viral replication. Tang WF, Yang SY, Wu BW, Jheng JR, Chen YL, Shih CH, Lin KH, Lai HC, Tang P, Horng JT, J Biol Chem 2007 282 8 5888 5898 17182608 (Pubitemid 47093796)
18. Incidence and case-fatality rates resulting from the 1998 enterovirus 71 outbreak in Taiwan. Lu CY, Lee CY, Kao CL, Shao WY, Lee PI, Twu SJ, Yeh CC, Lin SC, Shih WY, Wu SI, et al. J Med Virol 2002 67 2 217 223 10.1002/jmv.2210 11992582 (Pubitemid 34493435)
19. Infection with enterovirus 71 or expression of its 2A protease induces apoptotic cell death. Kuo RL, Kung SH, Hsu YY, Liu WT, J Gen Virol 2002 83 Pt 6 1367 1376 12029152
20. Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Chang LY, Lin TY, Huang YC, Tsao KC, Shih SR, Kuo ML, Ning HC, Chung PW, Kang CM, Pediatr Infect Dis J 1999 18 12 1092 1096 10.1097/00006454-199912000-00013 10608631
21. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Foo DG, Alonso S, Chow VT, Poh CL, Microb Infec 2007 9 11 1299 1306 10.1016/j.micinf.2007.06. 002 (Pubitemid 47539204)
22. Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. Yu CK, Chen CC, Chen CL, Wang JR, Liu CC, Yan JJ, Su IJ, J Biomed Sci 2000 7 6 523 528 10.1007/BF02253368 11060501
23. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL, Virus Res 2007 125 1 61 68 10.1016/j.virusres.2006.12.005 17222936 (Pubitemid 46413387)
24. In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Barnard DL, Hubbard VD, Smee DF, Sidwell RW, Watson KG, Tucker SP, Reece PA, Antimicrob Agents Chemother 2004 48 5 1766 1772 10.1128/AAC.48.5.1766- 1772.2004 15105133 (Pubitemid 38544387)
25. Pleconaril, a novel antipicornaviral agent. Florea NR, Maglio D, Nicolau DP, Pharmacotherapy 2003 23 3 339 348 10.1592/phco.23.3.339.32099 12627933 (Pubitemid 36259338)
26. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Hayden FG, Andries K, Janssen PA, Antimicrob Agents Chemother 1992 36 4 727 732 10.1128/AAC.36.4.727 1503435
27. Treatment of potentially life-threatening enterovirus infections with pleconaril. Rotbart HA, Webster AD, Clin Infect Dis 2001 32 2 228 235 10.1086/318452 11170912 (Pubitemid 32524792)
28. In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Zhang G, Zhou F, Gu B, Ding C, Feng D, Xie F, Wang J, Zhang C, Cao Q, Deng Y, et al. Arch Virol 2012 157 4 669 679 10.1007/s00705-011-1222-6 22245989
29. Design, synthesis, and structure-activity relationship of pyridyl imidazolidinones: a novel class of potent and selective human enterovirus 71 inhibitors. Shia KS, Li WT, Chang CM, Hsu MC, Chern JH, Leong MK, Tseng SN, Lee CC, Lee YC, Chen SJ, et al. J Med Chem 2002 45 8 1644 1655 10.1021/jm010536a 11931618 (Pubitemid 34293529)
30. Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone. Shih SR, Tsai MC, Tseng SN, Won KF, Shia KS, Li WT, Chern JH, Chen GW, Lee CC, Lee YC, et al. Antimicrob Agents Chemother 2004 48 9 3523 3529 10.1128/AAC.48.9.3523-3529.2004 15328120 (Pubitemid 39129354)
31. Lactoferrin inhibits enterovirus 71 infection by binding to VP1 protein and host cells. Weng TY, Chen LC, Shyu HW, Chen SH, Wang JR, Yu CK, Lei HY, Yeh TM, Antiviral Res 2005 67 1 31 37 10.1016/j.antiviral.2005.03.005 15916817 (Pubitemid 40798916)
32. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Matthews DA, Dragovich PS, Webber SE, Fuhrman SA, Patick AK, Zalman LS, Hendrickson TF, Love RA, Prins TJ, Marakovits JT, et al. Proc Natl Acad Sci U S A 1999 96 20 11000 11007 10.1073/pnas.96.20.11000 10500114 (Pubitemid 29487318)
33. A mammalian cell-based reverse two-hybrid system for functional analysis of 3C viral protease of human enterovirus 71. Lee JC, Shih SR, Chang TY, Tseng HY, Shih YF, Yen KJ, Chen WC, Shie JJ, Fang JM, Liang PH, et al. Anal Biochem 2008 375 1 115 123 10.1016/j.ab.2007.12.019 18190777
34. Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. Lu G, Qi J, Chen Z, Xu X, Gao F, Lin D, Qian W, Liu H, Jiang H, Yan J, et al. J Virol 2011 85 19 10319 10331 10.1128/JVI.00787-11 21795339
35. Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer. Tsai MT, Cheng YH, Liu YN, Liao NC, Lu WW, Kung SH, Antimicrob Agents Chemother 2009 53 2 748 755 10.1128/AAC.00841-08 19015331
36. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Patick AK, Brothers MA, Maldonado F, Binford S, Maldonado O, Fuhrman S, Petersen A, Smith GJ 3rd, Zalman LS, Burns-Naas LA, et al. Antimicrob Agents Chemother 2005 49 6 2267 2275 10.1128/AAC.49.6.2267-2275.2005 15917520 (Pubitemid 40734453)
37. Crystal structure of human enterovirus 71 3C protease. Cui S, Wang J, Fan T, Qin B, Guo L, Lei X, Wang M, Jin Q, J Mol Biol 2011 408 3 449 461 10.1016/j.jmb.2011.03.007 21396941
38. The structure of the 2A proteinase from a common cold virus: a proteinase responsible for the shut-off of host-cell protein synthesis. Petersen JF, Cherney MM, Liebig HD, Skern T, Kuechler E, James MN, EMBO J 1999 18 20 5463 5475 10.1093/emboj/18.20.5463 10523291 (Pubitemid 29486366)
39. Structure and dynamics of coxsackievirus B4 2A proteinase, an enyzme involved in the etiology of heart disease. Baxter NJ, Roetzer A, Liebig HD, Sedelnikova SE, Hounslow AM, Skern T, Waltho JP, J Virol 2006 80 3 1451 1462 10.1128/JVI.80.3.1451-1462.2006 16415022 (Pubitemid 43134102)
40. 2'-C-methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus. Goris N, De Palma A, Toussaint JF, Musch I, Neyts J, De Clercq K, Antiviral Res 2007 73 3 161 168 10.1016/j.antiviral.2006.09.007 17055073
41. Synthesis and antiviral activity of 5-substituted cytidine analogues: identification of a potent inhibitor of viral RNA-dependent RNA polymerases. Harki DA, Graci JD, Galarraga JE, Chain WJ, Cameron CE, Peterson BR, J Med Chem 2006 49 21 6166 6169 10.1021/jm060872x 17034123 (Pubitemid 44595194)
42. Ribavirin treatment of murine coxsackievirus B3 myocarditis with analyses of lymphocyte subsets. Kishimoto C, Crumpacker CS, Abelmann WH, J Am Coll Cardiol 1988 12 5 1334 1341 10.1016/0735-1097(88)92618-6 2844874
43. Lethal mutagenesis of picornaviruses with N-6-modified purine nucleoside analogues. Graci JD, Too K, Smidansky ED, Edathil JP, Barr EW, Harki DA, Galarraga JE, Bollinger JM Jr, Peterson BR, Loakes D, et al. Antimicrob Agents Chemother 2008 52 3 971 979 10.1128/AAC.01056-07 18180344 (Pubitemid 351358376)
44. Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71. Chen TC, Chang HY, Lin PF, Chern JH, Hsu JT, Chang CY, Shih SR, Antimicrob Agents Chemother 2009 53 7 2740 2747 10.1128/AAC.00101-09 19414569
45. Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid. He R, Adonov A, Traykova-Adonova M, Cao J, Cutts T, Grudesky E, Deschambaul Y, Berry J, Drebot M, Li X, Biochem Biophys Res Commun 2004 320 4 1199 1203 10.1016/j.bbrc.2004.06.076 15249217 (Pubitemid 38916671)
46. Structural analysis of inhibition mechanisms of aurintricarboxylic acid on SARS-CoV polymerase and other proteins. Yap Y, Zhang X, Andonov A, He R, Comput Biol Chem 2005 29 3 212 219 10.1016/j.compbiolchem.2005.04.006 15979041 (Pubitemid 40822861)
47. Inhibition of enterovirus 71 replication and the viral 3D polymerase by aurintricarboxylic acid. Hung HC, Chen TC, Fang MY, Yen KJ, Shih SR, Hsu JT, Tseng CP, J Antimicrob Chemother 2010 65 4 676 683 10.1093/jac/dkp502 20089540
48. Host factors in enterovirus 71 replication. Shih SR, Stollar V, Li ML, J Virol 2011 85 19 9658 9666 10.1128/JVI.05063-11 21715481
49. Far upstream element binding protein 2 interacts with enterovirus 71 internal ribosomal entry site and negatively regulates viral translation. Lin JY, Li ML, Shih SR, Nucleic Acids Res 2009 37 1 47 59 10.1093/nar/gkn901 19010963
50. Kaempferol inhibits enterovirus 71 replication and internal ribosome entry site (IRES) activity through FUBP and HNRP proteins. Tsai F-J, Lin C-W, Lai C-C, Lan Y-C, Lai C-H, Hung C-H, Hsueh K-C, Lin T-H, Chang HC, Wan L, et al. Food Chem 2011 128 2 312 322 10.1016/j.foodchem.2011.03.022
51. Synthesis of syn and anti isomers of 6-[[(hydroxyimino)phenyl]methyl]-1- [(1-methylethyl)sulfonyl]-1H-benzimidazol-2-am ine. Inhibitors of rhinovirus multiplication. Wikel JH, Paget CJ, DeLong DC, Nelson JD, Wu CY, Paschal JW, Dinner A, Templeton RJ, Chaney MO, Jones ND, et al. J Med Chem 1980 23 4 368 372 10.1021/jm00178a004 6247489 (Pubitemid 10091399)
52. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. Heinz BA, Vance LM, J Virol 1995 69 7 4189 4197 7769678
53. Genetic dissection of interaction between poliovirus 3D polymerase and viral protein 3AB. Hope DA, Diamond SE, Kirkegaard K, J Virol 1997 71 12 9490 9498 9371611 (Pubitemid 27492394)
54. Cis-acting lesions targeted to the hydrophobic domain of a poliovirus membrane protein involved in RNA replication. Giachetti C, Hwang SS, Semler BL, J Virol 1992 66 10 6045 6057 1326655
55. A bifunctional anti-enterovirus compound that inhibits replication and the early stage of enterovirus 71 infection. Arita M, Takebe Y, Wakita T, Shimizu H, J Gen Virol 2010 91 Pt 11 2734 2744 20660150
56. Interference of hepatitis C virus RNA replication by short interfering RNAs. Kapadia SB, Brideau-Andersen A, Chisari FV, Proc Natl Acad Sci U S A 2003 100 4 2014 2018 10.1073/pnas.252783999 12566571 (Pubitemid 36254565)
57. siRNA-directed inhibition of HIV-1 infection. Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK, Collman RG, Lieberman J, Shankar P, Sharp PA, Nat Med 2002 8 7 681 686 12042777 (Pubitemid 34778720)
58. Modulation of HIV-1 replication by RNA interference. Jacque JM, Triques K, Stevenson M, Nature 2002 418 6896 435 438 10.1038/nature00896 12087358 (Pubitemid 34826845)
59. Short interfering RNA confers intracellular antiviral immunity in human cells. Gitlin L, Karelsky S, Andino R, Nature 2002 418 6896 430 434 10.1038/nature00873 12087357 (Pubitemid 34826844)
60. RNA interference against enterovirus 71 infection. Sim AC, Luhur A, Tan TM, Chow VT, Poh CL, Virology 2005 341 1 72 79 10.1016/j.virol.2005.06.047 16083932 (Pubitemid 41356576)
61. Selective inhibition of enterovirus 71 replication by short hairpin RNAs. Lu WW, Hsu YY, Yang JY, Kung SH, Biochem Biophys Res Commun 2004 325 2 494 499 10.1016/j.bbrc.2004.10.062 15530419 (Pubitemid 39458021)
62. Inhibition of enterovirus 71 in virus-infected mice by RNA interference. Tan EL, Tan TM, Tak Kwong Chow V, Poh CL, Mol Ther 2007 15 11 1931 1938 10.1038/sj.mt.6300287 17712333 (Pubitemid 350011732)
63. Type I interferons protect mice against enterovirus 71 infection. Liu ML, Lee YP, Wang YF, Lei HY, Liu CC, Wang SM, Su IJ, Wang JR, Yeh TM, Chen SH, et al. J Gen Virol 2005 86 Pt 12 3263 3269 16298971
64. Potent inhibition of human enterovirus 71 replication by type I interferon subtypes. Yi L, He Y, Chen Y, Kung HF, He ML, Antivir Ther 2011 16 1 51 58 10.3851/IMP1720 21311108
65. Synergistic inhibition of enterovirus 71 replication by interferon and rupintrivir. Hung HC, Wang HC, Shih SR, Teng IF, Tseng CP, Hsu JT, J Infect Dis 2011 203 12 1784 1790 10.1093/infdis/jir174 21536800
66. Enterovirus 71 Disrupts Interferon Signaling by reducing the Interferon Receptor I. Lu J, Yi L, Zhao J, Yu J, Chen Y, Lin MC, Kung HF, He ML, J Virol 2012 86 7 3767 3776 10.1128/JVI.06687-11 22258259
67. Towards the design of combination therapy for the treatment of enterovirus infections. Thibaut HJ, Leyssen P, Puerstinger G, Muigg A, Neyts J, De Palma AM, Antiviral Res 2011 90 3 213 217 10.1016/j.antiviral.2011.03.187 21466823
68. Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Chumakov M, Voroshilova M, Shindarov L, Lavrova I, Gracheva L, Koroleva G, Vasilenko S, Brodvarova I, Nikolova M, Gyurova S, et al. Arch Virol 1979 60 3-4 329 340 228639 (Pubitemid 9221445)
69. A murine oral enterovirus 71 infection model with central nervous system involvement. Chen YC, Yu CK, Wang YF, Liu CC, Su IJ, Lei HY, J Gen Virol 2004 85 Pt 1 69 77 14718621
70. A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. Wang YF, Chou CT, Lei HY, Liu CC, Wang SM, Yan JJ, Su IJ, Wang JR, Yeh TM, Chen SH, et al. J Virol 2004 78 15 7916 7924 10.1128/JVI.78.15.7916-7924.2004 15254164 (Pubitemid 38944277)
71. Pyramidal and extrapyramidal involvement in experimental infection of cynomolgus monkeys with enterovirus 71. Nagata N, Shimizu H, Ami Y, Tano Y, Harashima A, Suzaki Y, Sato Y, Miyamura T, Sata T, Iwasaki T, J Med Virol 2002 67 2 207 216 10.1002/jmv.2209 11992581 (Pubitemid 34493434)
72. Differential localization of neurons susceptible to enterovirus 71 and poliovirus type 1 in the central nervous system of cynomolgus monkeys after intravenous inoculation. Nagata N, Iwasaki T, Ami Y, Tano Y, Harashima A, Suzaki Y, Sato Y, Hasegawa H, Sata T, Miyamura T, et al. J Gen Virol 2004 85 Pt 10 2981 2989 15448361 (Pubitemid 39360042)
73. Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Chen HL, Huang JY, Chu TW, Tsai TC, Hung CM, Lin CC, Liu FC, Wang LC, Chen YJ, Lin MF, et al. Vaccine 2008 26 23 2882 2889 10.1016/j.vaccine.2008.03.041 18450335
74. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Chen HF, Chang MH, Chiang BL, Jeng ST, Vaccine 2006 24 15 2944 2951 10.1016/j.vaccine.2005.12.047 16448730
75. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS, Vaccine 2001 20 5-6 895 904 11738755 (Pubitemid 34015831)
76. Formaldehyde-inactivated human enterovirus 71 vaccine is compatible for co-immunization with a commercial pentavalent vaccine. Chen CW, Lee YP, Wang YF, Yu CK, Vaccine 2011 29 15 2772 2776 10.1016/j.vaccine.2011.01.094 21315698
77. Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. Ong KC, Devi S, Cardosa MJ, Wong KT, J Virol 2010 84 1 661 665 10.1128/JVI.00999-09 19864378
78. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, Wen SQ, Liu Y, Yin WD, Li RC, Wang JZ, Vaccine 2012 30 22 3295 3303 10.1016/j.vaccine.2012.03.010 22426327